Aquestive (NASDAQ: AQST) CCO's 2,714-share tax withholding detailed

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. executive Sherry Korczynski, Chief Commercial Officer, reported a Form 4 transaction involving company common stock. On 2026-08-14, 2,714 shares of common stock were withheld by the issuer at $4.25 per share to satisfy her tax withholding obligation arising from the vesting of previously granted Restricted Stock Units (RSUs). After this tax-withholding disposition, she directly holds 235,689 shares of Aquestive Therapeutics common stock.

Insider Trade Summary

Net Seller: 2,714 shares

Net Sell 1 txn

Insider Korczynski Sherry

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	2,714	$4.25	$12K

Holdings After Transaction: Common Stock — 235,689 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Key Figures

Shares withheld for taxes: 2,714 shares Per-share value for withholding: $4.25 per share Shares owned after transaction: 235,689 shares

3 metrics

Shares withheld for taxes 2,714 shares Common stock withheld on 2026-08-14 to satisfy tax withholding obligation on RSU vesting

Per-share value for withholding $4.25 per share Value applied to the 2,714 shares withheld to cover tax liability

Shares owned after transaction 235,689 shares Direct holdings of Aquestive Therapeutics common stock following the tax-withholding disposition

Key Terms

Restricted Stock Units ("RSUs"), tax withholding obligation, withheld by the Issuer

3 terms

Restricted Stock Units ("RSUs") financial

"in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

tax withholding obligation financial

"to satisfy the Reporting Person's tax withholding obligation in connection with the vesting"

withheld by the Issuer financial

"Represents shares withheld by the Issuer to satisfy the Reporting Person's tax"

FAQ

What insider transaction did AQST executive Sherry Korczynski report on this Form 4?

Sherry Korczynski reported a tax-withholding disposition of 2,714 shares of Aquestive Therapeutics common stock. The shares were withheld by the company to cover taxes due upon the vesting of previously granted RSUs, not sold in an open-market trade.

How many AQST shares were involved in Sherry Korczynski’s 2026-08-14 Form 4 transaction?

The Form 4 reports 2,714 shares of Aquestive Therapeutics common stock. These shares were withheld by the issuer to satisfy Korczynski’s tax withholding obligation tied to vesting RSUs, rather than being bought or sold on the market.

At what price were the AQST shares valued in Sherry Korczynski’s tax-withholding transaction?

The withheld shares were valued at $4.25 per share. This per-share value is used to determine the amount of stock required to satisfy the tax withholding obligation arising from the vesting of Korczynski’s Restricted Stock Units.

How many AQST shares does Sherry Korczynski hold after this Form 4 transaction?

Following the reported tax-withholding disposition, Sherry Korczynski directly holds 235,689 shares of Aquestive Therapeutics common stock. This figure reflects her ownership after the issuer withheld 2,714 shares to cover the RSU-related tax obligation.

Was Sherry Korczynski’s AQST Form 4 transaction a market sale of shares?

No. The Form 4 specifies the transaction as shares withheld by the issuer to pay tax withholding on vesting RSUs. It is classified under code F, meaning it was for tax liability payment rather than a discretionary open-market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 05:34 PM Accepted by SEC EDGAR 08/17/2026 - 05:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Korczynski Sherry

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		F		2,714(1)	D	$4.25	235,689	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)